Mytheresa price target lowered to $9 from $11 at JPMorgan

JPMorgan analyst Matthew Boss lowered the firm’s price target on Mytheresa to $9 from $11 and keeps an Overweight rating on the shares. Managements of department stories and specialty softlines are seeing increased earnings visibility into fiscal 2023 given better inventory positions, reduced supply chain lead times and moderating freight/raw material costs, the analyst tells investors in a research note.